A Phase 3, First Line Study of Pemigatinib vs Gemcitabine/Cisplatin in Patients with Cholangiocarcinoma

Study Name A Phase 3, First Line Study of Pemigatinib vs Gemcitabine/Cisplatin in Patients with Cholangiocarcinoma ClinicalTrials.gov Identifier (if applicable) NCT03656536 Clinical Trial Category (check all that apply) First Line Therapy Study Center Institution Name Incyte Corporation Institution Address 1815 Augustine Cut Off City Wilmington State Delaware Zip Code 19803 Country United States Phone (855) 463-3463 Study Contacts Principal Investigator Tanios Bekaii-Saab, MD P.I. Phone (855) 463-9463 P.I. Email TBD@XYZ.com List additional Principal Investigators (include phone number and email) Please refer to the Clinical Trials. gov listing and contact the Incyte Help Line at 855-463-3463 for a site list Study Coordinator TBD Study Coordinator Phone (855) 463-3463 Study Coordinator Email TBD@XYZ.com List additional Study Coordinators (include phone number and email) Please refer to the Clinical Trials. gov listing and contact the Incyte Help Line at 855-463-3463 for a site list OVERVIEW – in layman’s terms (150 words max) This...

TELE-ABC

Study Name TELE-ABC ClinicalTrials.gov Identifier (if applicable) NCT03790111 Clinical Trial Category (check all that apply) First Line Therapy Other Novel Therapies Study Center Institution Name Lexicon Pharmaceuticals, Inc. Institution Address 8800 Technology Forest Place City The Woodlands State Texas Zip Code 77381 Country United States Phone (281) 863-3000 Website http://www.lexpharma.com Study Contacts Principal Investigator N/A P.I. Phone (000) 000-0000 P.I. Email NA@notapplicable.com Study Coordinator Karie Arnold Study Coordinator Phone (281) 863-3317 Study Coordinator Email karnold@lexpharma.com OVERVIEW – in layman’s terms (150 words max) There is a Screening Period of up to 42 days. This is followed by a Treatment Period with multiple cycles. Each cycle of the Treatment Period is 21 days. This period lasts until disease progression, signs of toxicity, or until the patient decides to stop the treatment. Next, there is a Follow-up Period that could last as long as 24 months. Enrollment 54 Study Start Date...

FUZE Clinical Trial

Study Name FUZE Clinical Trial ClinicalTrials.gov Identifier (if applicable) NCT03834220 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted Therapy Study Center Institution Name Massachusetts General Hospital Institution Address 165 Cambridge Street, Suite 302 City Boston State Massachusetts Zip Code 02114 Country United States Phone (617) 724-4000 Website https://patients.debiopharm.com/genetic-alterations List additional Institutions (include address, phone number, and website) United States, Arizona University of Arizona Cancer Center 1515 N Campbell Avenue Tucson, AZ 85724 Phone: +1 (520) 626-7866 United States, California Moores University of California, San Diego Cancer Center 3855 Health Sciences Drive MC 0698 La Jolla, CA 92093 Phone: +1 (858) 246-1102 University of California, San Francisco 1600 Divisadero, Suite B-718 San Francisco, CA 94115 Phone: +1 (510) 579-5972 United States, Florida H. Lee Moffitt Cancer Center & Research Institute 1209 Magnolia Drive FOW-EDU Tampa, FL 33612 Phone: +1 (813) 745-2226 United States, Louisiana Tulane Cancer...

2019 Annual Conference Videos

All of the presentations at our 2019 Annual Conference are online and waiting to be viewed! Visit our Conference in Review page for photos, a recap video and videos from many of the presentations, or if you prefer, visit our YouTube Channel, where we have all of the Conference Videos arranged into a...

Changing Lives Fundraiser

EVENT INFORMATION: Friday, February 15, 2019 — 6:00 – 10:00 PM The Salem Waterfront Hotel — 225 Derby Street Salem, MA 01970 Food Open Cash Bar Silent Auction Fun & Dancing with DJ Nick! Theme: Wear Green! Prize awarded for best dressed! To purchase tickets, please contact Caitlin Fortuna at: https://changinglivesfund.wixsite.com/fundraiser Adults: $23 Children: $20 (Under 3 yrs: Free) Event proceeds after expenses will go to the Cholangiocarcinoma...

Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Study Name Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy ClinicalTrials.gov Identifier (if applicable) NCT03639935 Clinical Trial Category (check all that apply) Beyond First Line Therapy Study Center Institution Name University of Michigan Institution Address 1500 E Medical Center Dr., Rogel Cancer Center City Ann Arbor State Michigan Zip Code 48109 Country United States Phone (734) 936-4991 List additional Institutions (include address, phone number, and website) Dana-Farber Cancer Institute Vanderbilt University Medical Center Study Contacts Principal Investigator Vaibhav Sahai, MD P.I. Phone (734) 936-4991 P.I. Email CTSU-Oncology-Multisite@med.umich.edu Study Coordinator Dominique Dippman, RN Study Coordinator Phone (734) 647-8902 Study Coordinator Email CTSU-Oncology-Multisite@med.umich.edu OVERVIEW – in layman’s terms (150 words max) The investigators are studying the benefit of daily oral targeted therapy (rucaparib) in conjunction with every 2 week infusional immunotherapy (nivolumab) in...

Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Study Name Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors ClinicalTrials.gov Identifier (if applicable) NCT03678883 Clinical Trial Category (check all that apply) Beyond First Line Therapy Chemotherapy Targeted Therapy Other Novel Therapy Study Center Institution Name Rhode Island Hospital Institution Address rovidence, Rhode Island, United States, 02903 City Providence State Rhode Island Zip Code 02903 Country United States Phone (401) 444-3234 Website https://www.lifespan.org/centers-services/cancer-research-and-clinical-trials Study Contacts Principal Investigator Benedito Carneiro, MD P.I. Phone (401) 444-3234 P.I. Email Benedito.Carneiro@Lifespan.org Study Coordinator Jennifer Renaud Study Coordinator Phone (401) 444-3234 Study Coordinator Email JRenaud@Lifespan.org OVERVIEW – in layman’s terms (150 words max) A clinical trial of a new drug known as 9-ING-41, that will take place in patients with tumors or cancers that affect the blood and lymph system. 9-ING-41...

Tree Topp

Study Name Tree Topp ClinicalTrials.gov Identifier (if applicable) NCT03093870 Clinical Trial Category (check all that apply) Beyond First Line Therapy Chemotherapy Study Center Institution Name UT MD Anderson Cancer Center Institution Address University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 426, FC10.2051 City Houston State TX Zip Code 77030 Phone 1-877-250-3770 Website mdanderson.org Study Contacts Principal Investigator Dr. Milind Javle P.I. Phone (713) 794-1623 P.I. Email mjavle@mdanderson.org Study Coordinator Kimberly Ross Study Coordinator Phone 713-794-1623 Study Coordinator Email kdross@mdanderson.org List additional Study Coordinators (include phone number and email) Charlotte, North Carolina – Levine Cancer Institute, Carolinas Healthcare System 1021 Morehead Medical Dr.  Charlotte, NC  28204; (980) 442-2000 Contact: Study Coordinator – Melani Terry, (980)-442-2157, Melani.Terry@atriumhealth.org Dallas, Texas – Texas Oncology, P.A., Texas Oncology Sammons Cancer Center 3410 Worth Street, Suite 730 , Dallas, TX 75246; www.texasoncology.com Contact: Study Coordinator -Catinna Mallett, (214)-370-1949 Detroit, Michigan – Karmanos Cancer...

GNS561-CL-I-Q-0211: Phase 1/2 Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients with Primary Liver Cancer which includes Intrahepatic cholangiocarcinoma patients

Study Name GNS561-CL-I-Q-0211: Phase 1/2 Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients with Primary Liver Cancer which includes Intrahepatic cholangiocarcinoma patients ClinicalTrials.gov Identifier (if applicable) NCT03316222 Clinical Trial Category (check all that apply) Beyond First Line Therapy Chemotherapy Other Novel Therapy Study Center Institution Name Memorial Sloan Kettering Institution Address 300 E 53rd St City New York State New York Zip Code 10065 Study Contacts Principal Investigator Pr James Harding P.I. Phone (646) 888-4314 P.I. Email hardinj1@mskcc.org List additional Principal Investigators (include phone number and email) Pr Ghassan Abou-Alfa, (646) 888-4184, abou-alg@mskcc.org Study Coordinator Amanda Simms Study Coordinator Phone (646) 888-4314 Study Coordinator Email simmsa@mskcc.org List additional Study Coordinators (include phone number and email) Brittanie Millans, millangb@mskcc.org OVERVIEW – in layman’s terms (150 words max) This is a multicenter, open-label, uncontrolled, repeat-dose phase 1/2a study designed to evaluate the safety profile and to determine...

The 2019 Annual Conference T-Shirt Design Contest

CCF is excited to announce our Annual Conference t-shirt logo contest. The logos will be printed on a white sport t-shirt with green 3/4 sleeves. Contest Rules Use this entry form to submit your logo design Limit design to a maximum of 2 colors Limit design to no larger than 10 inches square 5 designs will be posted on our Facebook page for voting. The winning design will be the logo with the most “likes” Submission deadline is Sunday, September 30th Questions? Email jordan.giles@cholangiocarcinoma.org   Name* First Last What is your relationship with cholangiocarcinoma?Patient (personally diagnosed)CaregiverFriend or Relative of PatientOtherAddress Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarrussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongo, Democratic Republic of theCongo, Republic of theCook IslandsCosta RicaCôte d'IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatini (Swaziland)EthiopiaFalkland...

Thoughts and Memories of Marion Schwartz

Marion and I worked together daily for over 10 years building the foundation and we’ve talked often since her retirement. She worked with many of you over the years to make sure the patient voice was considered in all endeavors and she admired the way you treated “her” patients. She took great pride in her work and considered you friends and colleagues. Today, at CCF we will be thinking of Marion, all she accomplished and all those she personally shepherded through life with compassion and great tenderness. She had a wonderful gift that she shared with all of us. She was and will continue to be an enormous blessing to our community. Love to all, Stacie C. Lindsey President & Founder Cholangiocarcinoma Foundation We will all treasure great memories of Marion and her passion for improving care for patients with cholangiocarcinoma. Deepest condolences to her family. Dr. Lewis Roberts...

A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given with Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) alone in Patients with Intrahepatic Cholangiocarcinoma

Study Name A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given with Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) alone in Patients with Intrahepatic Cholangiocarcinoma ClinicalTrials.gov Identifier (if applicable) NCT03086993 Clinical Trial Category (check all that apply) Chemotherapy First Line Therapy Targeted Therapy Study Center Institution Name Duke University Medical Center Institution Address 30 Duke Medicine Circle City Durham State North Carolina Zip Code 27710 Study Contacts Principal Investigator Sabino Zani P.I. Phone (919) 684-6553 P.I. Email sabino.zani@duke.edu Study Coordinator Kimberly Turnage Study Coordinator Phone (919) 681-5559 Study Coordinator Email kimberly.turnage@duke.edu OVERVIEW – in layman’s terms (150 words max) Patients with intrahepatic cholangiocarcinoma who enroll in this study will receive either Melphalan with the investigational Hepatic Delivery System (called Melphalan/HDS) or Cisplatin and Gemcitabine alone, which is standard of care.  Patients who enroll will receive gem/cis followed by melphalan, compared to gem/cis. Enrollment 5...
Translate »

Pin It on Pinterest